An ongoing dialogue on HIV/AIDS, infectious diseases,
October 23rd, 2011
TB, Timing of Antiretroviral Therapy, and Being a Lumper Rather Than a Splitter
Three key papers on timing of ART in patients with TB have just been published in the New England Journal of Medicine.
Fortunately, Carlos Del Rio has done a bang-up job summarizing them in Journal Watch AIDS Clinical Care.
And if you’re wondering how we got our title for Carlos’ piece, here’s an e-mail between our Executive Editor to me a few weeks ago:
Hi Paul-
Later this month, NEJM will be publishing three articles on the timing of ART initiation relative to TB treatment. I assume we should cover these?
Cath
To which I responded:
Yep. And they all can be summarized as follows: “TB + low CD4 = start ART sooner rather than later”.
Yes, there are lots more data from these studies than this simple equation, but my response was a reminder that, despite being a thrice-certified ID specialist, I tend to be more of a lumper rather than a splitter — which makes me feel somewhat deficient in our field.
Oh well.
Of course even the less detail-obsessed ID docs like me probably score pretty high on the OCD-meter, so I can take some comfort in that.
Categories: HIV, Infectious Diseases, Patient Care, Research
Tags: antiretroviral therapy, ART, HIV, New England Journal of Medicine, TB, tuberculosis
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 August 6, 2026Bundibugyo virus, a filovirus, is currently spreading in the Democratic Republic of Congo. This report presents early data on symptoms and illness severity as well as diagnostic challenges.
- Ebola at 50 — Lessons for Outbreak Response and Preparedness August 6, 2026An accurate history of Ebola begins with partnerships, including those between responders and the populations they serve. One of its key lessons is that equity must be integral to outbreak preparedness.
- Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines August 6, 2026The Bundibugyo virus outbreak in the DRC and Uganda has focused concern on potential countermeasures. Investigators assessed cross-reactive immune responses in serum obtained during previous Ebola vaccine trials.
- The Inequality–Pandemic Cycle — Rethinking Preparedness August 6, 2026Increasing pandemic frequency and increasing economic inequality are creating a self-reinforcing cycle. What’s needed is therefore a new, inequality-informed approach to pandemic preparedness.
- The Social Contract of Bundibugyo Ebola Isolation August 6, 2026The lack of vaccines and disease-specific therapeutics for Bundibugyo Ebola has dramatically affected the community’s perception of Ebola treatment centers. In this context, trust becomes critical.
- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 August 6, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
